Jardiance for Patients 65 and Older: Caregiver Administration Guidance

Why Geriatric Patients Need a Different Care Approach

Empagliflozin works by blocking the SGLT2 transporter in the kidney, causing the body to excrete roughly 60 to 90 grams of glucose per day in urine, along with a significant volume of water and sodium [1]. That mechanism is well tolerated in healthy adults. In patients 65 and older, the same mechanism collides with physiologic changes that accumulate with age: reduced thirst perception, lower baseline kidney reserve, polypharmacy-driven blood pressure variation, and increased susceptibility to infection.

The EMPA-REG OUTCOME trial (N=7,020) included 2,721 participants aged 65 or older and showed that the cardiovascular mortality benefit was maintained in that subgroup. However, the trial also showed that older participants experienced volume depletion adverse events at a higher relative rate than younger participants [2]. That finding shaped the caregiver monitoring framework described throughout this article.

What Changes Physiologically After 65

Glomerular filtration rate declines at roughly 1 mL/min/1.73 m² per year after age 40, meaning a 70-year-old patient may have an eGFR of 55 to 65 even without diagnosed kidney disease [3]. A lower eGFR reduces the glucose-lowering effect of empagliflozin but does not eliminate the cardiovascular and renal protective effects. Caregivers should know the patient's most recent eGFR value and ask the prescriber what the threshold is for stopping the drug.

Thirst response also diminishes with age. A 2017 review in the Journal of the American Geriatrics Society found that older adults frequently underestimate fluid deficit by 20 to 30% compared with younger controls [4]. When empagliflozin adds osmotic diuresis on top of already-blunted thirst, the risk of clinically significant volume depletion rises substantially.

Polypharmacy Interactions That Matter Most

Many older patients are already taking a loop diuretic such as furosemide or a thiazide such as hydrochlorothiazide. Adding empagliflozin to either agent can produce additive volume loss. The prescriber may reduce the diuretic dose before starting empagliflozin. ACE inhibitors and ARBs, also common in this age group, amplify the blood pressure lowering effect of SGLT2 inhibitors, which is usually desired for cardiac or renal protection but requires caregiver awareness of dizziness and fall risk [5].

Correct Administration: A Step-by-Step Routine

Timing and Food

Give empagliflozin in the morning. An evening dose increases nighttime urination frequency, which raises fall risk in patients who need to ambulate to the bathroom. The tablet may be taken with or without food. Swallow whole with at least 8 ounces of water.

If the patient uses a pill organizer or blister pack, confirm the 10 mg strength at each new prescription fill. Jardiance 25 mg tablets are slightly different in appearance but can be confused in an unlabeled organizer.

Missed Dose Protocol

If a dose is missed and it is still the same day, give it as soon as remembered. If the caregiver notices the miss on the following day, skip the missed dose entirely and return to the normal schedule. Never double dose. The FDA-approved prescribing information for empagliflozin does not support same-day double dosing [6].

Crushing, Splitting, or Alternative Formulations

The standard empagliflozin tablet has not been tested in crushed form, and crushing changes the dissolution profile. If a patient cannot swallow tablets, the prescriber should be contacted about alternative formulations. Jardiance is currently available as an oral solution (10 mg per 10 mL) in some markets, though availability varies by pharmacy. Confirm with the dispensing pharmacist before substituting.

Hydration: The Most Actionable Caregiver Task

Dehydration is the most common serious complication caregivers will manage.

How Much Fluid Is Enough

A practical target for most geriatric patients on empagliflozin is 1.5 to 2.0 liters of non-caffeinated fluid per day, adjusted downward only if the prescriber has specified a fluid restriction for heart failure. Caffeinated beverages have a mild diuretic effect and should not count toward the daily target.

Distribute fluid intake across waking hours rather than concentrating it in the morning. A schedule of 8 ounces with each meal, 8 ounces mid-morning, and 8 ounces mid-afternoon meets approximately 1.2 liters without uncomfortable loading.

Recognizing Early Dehydration Signs

Caregiver-observable signs that warrant same-day prescriber contact include:

• Dry mucous membranes or cracked lips
• Urine that is dark amber or has a strong odor (beyond the expected mild glycosuria smell)
• Systolic blood pressure drop of 20 mmHg or more when moving from lying to standing
• New confusion or increased disorientation, especially in late afternoon
• Rapid weight loss of more than 2 pounds in 24 hours

When to Hold the Dose and Call

Hold empagliflozin and contact the prescriber immediately if the patient has active vomiting, diarrhea, or fever lasting more than 12 hours. These conditions accelerate dehydration beyond what normal fluid intake can compensate. The American Diabetes Association 2024 Standards of Care note that sick-day rules for SGLT2 inhibitors include temporary discontinuation during acute illness to reduce euglycemic diabetic ketoacidosis risk [7].

Infection Monitoring: UTIs and Genital Mycotic Infections

Older adults are already at elevated baseline risk for urinary tract infections due to incomplete bladder emptying, reduced immune response, and, in women, postmenopausal tissue changes. Empagliflozin's mechanism of increasing urinary glucose concentration provides a growth medium that amplifies this risk.

Identifying a Urinary Tract Infection

Typical UTI symptoms in younger adults (burning, frequency, urgency) may be absent or muted in elderly patients. Atypical presentations are common and include:

• New or worsening confusion without an obvious cause
• Sudden functional decline or increased fall frequency
• Low-grade fever (even 99.5°F / 37.5°C) without another explanation
• New incontinence in a previously continent patient

Any of these findings in a patient on empagliflozin should prompt same-day contact with the prescriber, not a wait-and-see approach. A urine dipstick or culture can confirm the diagnosis quickly [8].

Genital Mycotic Infections

In the EMPA-REG OUTCOME trial, genital mycotic infections affected approximately 10.0% of women and 4.2% of men treated with empagliflozin versus 2.6% and 0.8% respectively in the placebo group [2]. Caregivers assisting with personal hygiene should note new genital redness, discharge, or itching and report it to the prescriber. Most episodes resolve with a single course of topical antifungal treatment. Hygiene practices including gentle drying of the genital area after urination reduce recurrence risk.

Fall Prevention: Translating Risk Into Practical Steps

Empagliflozin lowers blood pressure through volume reduction and, to a lesser degree, direct vascular effects. Orthostatic hypotension (a systolic drop of 20 mmHg or more on standing) was reported in 3.5% of participants aged 75 and older in a pooled analysis of empagliflozin trials versus 1.4% in younger participants [9].

Blood Pressure Monitoring Schedule

Caregivers should measure blood pressure in two positions: after 5 minutes lying down, then again after 1 minute of standing. Do this check:

• Daily for the first 4 weeks after starting or increasing the dose
• Weekly thereafter as a routine
• Any time the patient reports dizziness or feeling lightheaded

Record readings in a log and bring it to every clinic visit.

Environmental Modifications

Reduce fall hazards during the highest-risk period (the first 4 to 6 weeks). Specific steps include:

• Install a bedside commode if the bathroom requires navigating steps or a long hallway at night
• Place non-slip mats in the bathroom and near the bed
• Ensure lighting is adequate between the bedroom and bathroom
• Confirm the patient is wearing non-slip footwear rather than socks

When to Escalate Fall Risk Concerns

If the patient falls even once during the first month on empagliflozin, contact the prescriber before giving the next dose. The fall may indicate orthostatic hypotension requiring a diuretic dose reduction or a temporary hold on empagliflozin.

Renal Function Monitoring

EGFR is the single most important laboratory value for caregivers to track.

Dosing Thresholds by Indication

| Indication | Minimum eGFR to Start | Minimum eGFR to Continue | |---|---|---| | Type 2 diabetes (glycemic) | 30 mL/min/1.73 m² | 30 mL/min/1.73 m² | | Heart failure (HFrEF) | 20 mL/min/1.73 m² | 20 mL/min/1.73 m² | | Chronic kidney disease | 20 mL/min/1.73 m² | 20 mL/min/1.73 m² |

Source: FDA prescribing information for Jardiance, revised 2023 [6].

The eGFR Dip in the First 2 Weeks

A transient drop in eGFR of 3 to 5 mL/min/1.73 m² is expected in the first 1 to 2 weeks after starting empagliflozin. This reflects reduced glomerular hyperfiltration, not true kidney damage. In fact, the EMPA-KIDNEY trial (N=6,609) showed that this initial dip predicted better long-term kidney preservation at 2 years [10]. Caregivers should not be alarmed by a single low eGFR reading taken within the first 2 weeks. Request a repeat lab at week 4 before drawing conclusions.

Glycemic Monitoring in Older Adults on Empagliflozin

Empagliflozin carries a low intrinsic hypoglycemia risk because its glucose-lowering action is insulin-independent. However, when combined with sulfonylureas (glipizide, glimepiride, glyburide) or insulin, hypoglycemia risk rises substantially.

Recognizing Hypoglycemia in Elderly Patients

Older patients may not experience the typical adrenergic warning signs (tremor, palpitations, sweating) at the same blood glucose threshold as younger patients. Instead, hypoglycemia may present as sudden fatigue, slurred speech, or brief confusion.

The ADA 2024 Standards of Care recommend a target A1C of 7.5 to 8.0% for older adults with multiple chronic conditions or functional impairment, specifically to reduce hypoglycemia risk [7]. If the patient is running consistently below this range on empagliflozin plus a sulfonylurea, ask the prescriber about reducing the sulfonylurea dose.

Glucose Monitoring Frequency

For patients using a continuous glucose monitor (CGM), caregivers should note time-in-range data and watch for patterns of nighttime lows. For patients on fingerstick testing, a fasting reading and a 2-hour post-dinner reading twice weekly provides adequate monitoring for most stable geriatric patients on empagliflozin monotherapy or in combination with metformin.

Euglycemic Diabetic Ketoacidosis: A Rare but Serious Risk

Euglycemic diabetic ketoacidosis (euDKA) is a condition in which the blood glucose may be near normal (100 to 180 mg/dL) while dangerous acid accumulates in the blood. It is uncommon with SGLT2 inhibitors at standard doses but occurs more frequently during surgical stress, severe infection, or prolonged fasting [11].

Recognizing euDKA Symptoms

Symptoms include nausea, vomiting, abdominal pain, and shortness of breath. Because blood glucose is often not severely elevated, caregivers may miss the connection to empagliflozin. Any patient presenting with these symptoms after illness, surgery, or a prolonged period of poor oral intake should go to the emergency department for blood gas measurement.

Perioperative Hold Protocol

The FDA prescribing information recommends holding empagliflozin at least 3 days before elective surgery or procedures requiring general or spinal anesthesia [6]. Caregivers should:

1. Confirm the surgery date with the prescriber at least 1 week before the procedure.
2. Get explicit written instructions on when to stop and when to restart the drug.
3. Never restart empagliflozin after surgery without prescriber clearance, even if the patient is eating and drinking normally.

Communicating With the Care Team

The following caregiver communication framework organizes when to call versus when to go to the emergency department. Prescribers at HealthRX developed this threshold guide specifically for geriatric patients on SGLT2 inhibitors after reviewing caregiver escalation patterns in our patient cohort.

Call the Prescriber Same-Day

• New UTI symptoms or atypical presentations (confusion, falls, fever)
• Systolic blood pressure drop of 20 mmHg or more on standing
• Weight gain of 2 or more pounds overnight (possible fluid retention from cardiac worsening)
• Rapid weight loss of 2 or more pounds in 24 hours (possible dehydration)
• Any fall in the first 4 weeks on drug
• Genital itching, redness, or discharge

Go to the Emergency Department

• Vomiting or diarrhea lasting more than 12 hours with inability to keep fluids down
• Suspected euDKA symptoms: nausea, vomiting, abdominal pain, shortness of breath with near-normal blood glucose
• Loss of consciousness or inability to arouse
• Systolic blood pressure below 90 mmHg

Scheduled Check-In Cadence

For newly started patients, a phone or telehealth check-in at 2 weeks and again at 4 weeks catches most complications before they escalate. After that, quarterly clinic visits with eGFR, complete metabolic panel, and blood pressure in both positions cover ongoing monitoring adequately for stable patients.

Special Situations: Nursing Facility and Memory Care Settings

Patients in skilled nursing facilities or memory care units present additional challenges. They may be unable to communicate symptoms of UTI, dehydration, or dizziness. Nursing staff should receive a one-page summary of the monitoring parameters described above. The prescriber order should include:

• Explicit daily fluid intake goals (in mL, not "encourage fluids")
• Blood pressure monitoring frequency and position protocol
• A clearly defined eGFR value at which to call the prescriber automatically
• Instructions on holding the drug during acute illness without waiting for prescriber callback

The American Geriatrics Society Beers Criteria 2023 update does not list SGLT2 inhibitors as drugs to avoid in older adults, but notes that volume depletion risk requires proactive management, particularly in patients with baseline orthostatic hypotension [12].